These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23892183)

  • 21. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical R&D: the road to positive returns.
    David E; Tramontin T; Zemmel R
    Nat Rev Drug Discov; 2009 Aug; 8(8):609-10. PubMed ID: 19644471
    [No Abstract]   [Full Text] [Related]  

  • 23. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
    Dierks RML; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can quantitative pharmacology improve productivity in pharmaceutical research and development?
    Patel M; Bueters T
    Expert Opin Drug Discov; 2020 Oct; 15(10):1111-1114. PubMed ID: 32511018
    [No Abstract]   [Full Text] [Related]  

  • 27. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
    Schuhmacher A; Gassmann O; McCracken N; Hinder M
    J Transl Med; 2018 May; 16(1):119. PubMed ID: 29739427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The changing structure of the pharmaceutical industry.
    Cockburn IM
    Health Aff (Millwood); 2004; 23(1):10-22. PubMed ID: 15002624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug discovery in pharmaceutical industry: productivity challenges and trends.
    Khanna I
    Drug Discov Today; 2012 Oct; 17(19-20):1088-102. PubMed ID: 22627006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Looking outward: content as a service starts to make sense.
    Sherlock A
    Drug Discov Today; 2013 Jan; 18(1-2):1-3. PubMed ID: 23041498
    [No Abstract]   [Full Text] [Related]  

  • 33. A call for sharing: adapting pharmaceutical research to new realities.
    Munos BH; Chin WW
    Sci Transl Med; 2009 Dec; 1(9):9cm8. PubMed ID: 20368187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open PHACTS: semantic interoperability for drug discovery.
    Williams AJ; Harland L; Groth P; Pettifer S; Chichester C; Willighagen EL; Evelo CT; Blomberg N; Ecker G; Goble C; Mons B
    Drug Discov Today; 2012 Nov; 17(21-22):1188-98. PubMed ID: 22683805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helping science to succeed: improving processes in R&D.
    Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
    Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rebuilding the R&D engine in big pharma.
    Garnier JP
    Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Creating knowledge structures in the pharmaceutical industry: the increasing significance of virtual organisation.
    Salazar A; Howells J
    World Hosp Health Serv; 2000; 36(2):6-10, 44-5. PubMed ID: 11214458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation.
    Shi YZ; Hu H; Wang C
    Global Health; 2014 Nov; 10():78. PubMed ID: 25406839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.